Literature DB >> 32287355

Randomized, double-masked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjects.

Edward J Petrus1, Kenneth A Lawson2, Luke R Bucci3, Kenneth Blum4.   

Abstract

This report of a randomized, double-masked, placebo-controlled clinical study demonstrates the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjects. Subjects in the zinc and placebo groups were evenly matched with respect to sex, race/ethnicity, allergy test status, and age. Overall symptom duration was significantly less in the zinc group than in the placebo group (mean, 3.8 day vs 5.1 days). The mean severity rating for all symptoms was lower in the zinc group than in the placebo group; this difference, however, was not statistically significant. Allergy-positive subjects who used zinc had a statistically significant shorter duration of nasal symptoms than allergy-negative subjects (3.5 days vs 7.6 days). In conclusion, we propose that zinc acetate lozenges may significantly shorten the duration of common cold symptoms and relieve symptoms associated with allergies.
Copyright © 1998 Published by Elsevier Inc.

Entities:  

Keywords:  allergies; common cold; lozenges; zinc acetate

Year:  2001        PMID: 32287355      PMCID: PMC7118419          DOI: 10.1016/S0011-393X(98)85058-3

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  27 in total

1.  The effect of trace elements on the growth and fermantation by oral streptococci and actinomyces.

Authors:  I H Gallagher; T W Cutress
Journal:  Arch Oral Biol       Date:  1977       Impact factor: 2.633

2.  How does zinc modify the common cold? Clinical observations and implications regarding mechanisms of action.

Authors:  S G Novick; J C Godfrey; N J Godfrey; H R Wilder
Journal:  Med Hypotheses       Date:  1996-03       Impact factor: 1.538

3.  Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds.

Authors:  B M Farr; E M Conner; R F Betts; J Oleske; A Minnefor; J M Gwaltney
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

4.  Modulation of histamine release from human basophils in vitro by physiological concentrations of zinc.

Authors:  G Marone; S R Findlay; L M Lichtenstein
Journal:  J Pharmacol Exp Ther       Date:  1981-05       Impact factor: 4.030

5.  Zinc and infection.

Authors:  B Sugarman
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

6.  Histamine release from mast cells by compound 48/80. The membrane action of zinc.

Authors:  W Kazimierczak
Journal:  Agents Actions       Date:  1974-12

7.  A meta-analysis of zinc salts lozenges and the common cold.

Authors:  J L Jackson; C Peterson; E Lesho
Journal:  Arch Intern Med       Date:  1997-11-10

8.  Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges.

Authors:  W Al-Nakib; P G Higgins; I Barrow; G Batstone; D A Tyrrell
Journal:  J Antimicrob Chemother       Date:  1987-12       Impact factor: 5.790

9.  Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial.

Authors:  M L Macknin; M Piedmonte; C Calendine; J Janosky; E Wald
Journal:  JAMA       Date:  1998-06-24       Impact factor: 56.272

Review 10.  Epidemiology, pathogenesis, and treatment of the common cold.

Authors:  R B Turner
Journal:  Ann Allergy Asthma Immunol       Date:  1997-06       Impact factor: 6.347

View more
  9 in total

1.  Zinc Acetate Lozenges May Improve the Recovery Rate of Common Cold Patients: An Individual Patient Data Meta-Analysis.

Authors:  Harri Hemilä; James T Fitzgerald; Edward J Petrus; Ananda Prasad
Journal:  Open Forum Infect Dis       Date:  2017-04-03       Impact factor: 3.835

2.  Zinc Supplementation Reduces Common Cold Duration among Healthy Adults: A Systematic Review of Randomized Controlled Trials with Micronutrients Supplementation.

Authors:  Min Xian Wang; Shwe Sin Win; Junxiong Pang
Journal:  Am J Trop Med Hyg       Date:  2020-04-23       Impact factor: 2.345

Review 3.  Efficacy of zinc against common cold viruses: an overview.

Authors:  Darrell Hulisz
Journal:  J Am Pharm Assoc (2003)       Date:  2004 Sep-Oct

4.  The Effect of a Multivitamin and Mineral Supplement on Immune Function in Healthy Older Adults: A Double-Blind, Randomized, Controlled Trial.

Authors:  Mary L Fantacone; Malcolm B Lowry; Sandra L Uesugi; Alexander J Michels; Jaewoo Choi; Scott W Leonard; Sean K Gombart; Jeffrey S Gombart; Gerd Bobe; Adrian F Gombart
Journal:  Nutrients       Date:  2020-08-14       Impact factor: 5.717

5.  Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis.

Authors:  Ajibola Ibraheem Abioye; Sabri Bromage; Wafaie Fawzi
Journal:  BMJ Glob Health       Date:  2021-01

Review 6.  Quantile Treatment Effect of Zinc Lozenges on Common Cold Duration: A Novel Approach to Analyze the Effect of Treatment on Illness Duration.

Authors:  Harri Hemilä; Elizabeth Chalker; Janne Tukiainen
Journal:  Front Pharmacol       Date:  2022-02-01       Impact factor: 5.810

Review 7.  Zinc lozenges as cure for the common cold--a review and hypothesis.

Authors:  George A Eby
Journal:  Med Hypotheses       Date:  2009-11-10       Impact factor: 1.538

8.  Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial.

Authors:  Hedieh Ahmadi; Seyedeh Shabnam Mazloumi-Kiapey; Omid Sadeghi; Morteza Nasiri; Fariborz Khorvash; Tayebeh Mottaghi; Gholamreza Askari
Journal:  Nutr J       Date:  2020-09-14       Impact factor: 3.271

9.  Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials.

Authors:  Jennifer Hunter; Susan Arentz; Joshua Goldenberg; Guoyan Yang; Jennifer Beardsley; Stephen P Myers; Dominik Mertz; Stephen Leeder
Journal:  BMJ Open       Date:  2021-11-02       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.